Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-01-07
4 Insiders File Cidara Therapeutics (CDTX) Form 4 - January 07, 2026
4 Cidara Therapeutics Inc. insiders traded 23.8M CDTX shares worth $4121.9M in this Form 4 filing, reported to the SEC on 2026-01-07.
- Insider
- 4 insidersincl. Kolchinsky Peter
- Issuer
- Cidara Therapeutics Inc. CDTX · NASDAQ
- Filed
- Period
- 2026-01-07
- Accession
- 0001231919-26-000031
- Source
- Official filing on sec.gov ↗
Transactions (8)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Kolchinsky Peter | 2026-01-07 | Buy | 1.3M | $0.00 | $128.68 | Indirect |
| Kolchinsky Peter | 2026-01-07 | Sell | 4.7M | $221.50 | $1030.5M | Indirect |
| Ra Capital Healthcare Fund Lp | 2026-01-07 | Buy | 1.3M | $0.00 | $128.68 | Indirect |
| Ra Capital Healthcare Fund Lp | 2026-01-07 | Sell | 4.7M | $221.50 | $1030.5M | Indirect |
| Ra Capital Management, L.p. | 2026-01-07 | Buy | 1.3M | $0.00 | $128.68 | Indirect |
| Ra Capital Management, L.p. | 2026-01-07 | Sell | 4.7M | $221.50 | $1030.5M | Indirect |
| Shah Rajeev M. | 2026-01-07 | Buy | 1.3M | $0.00 | $128.68 | Indirect |
| Shah Rajeev M. | 2026-01-07 | Sell | 4.7M | $221.50 | $1030.5M | Indirect |
| Net change | −13.5M | −$4121.9M | ||||
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Track CDTX insider activity
Get alerted when Cidara Therapeutics Inc. executives buy or sell their shares.